MRTNZ

MRTNZ Investment Office · S&P 500 · The 360 Vantage

BIIB · NASDAQ-GS

Biogen Inc.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances)

Reference price$205.61As of Jul 28, 2026
Market capitalization$30.36B
52-week range$124.56–$219.72
S&P 500 portfolio weight0.05%
Data qualitycomplete

Street view

Analyst targets

Published sell-side aggregation—not an MRTNZ forecast.

Low$157.00-23.6% vs. reference
Average$226.48+10.2% vs. reference
High$300.00+45.9% vs. reference
19 Buy9 Hold1 Sell

Forward calendar

Current earnings expectations

Consensus may change until the company reports.

Expected reportNot availableJun 2026
Consensus EPS$1.0912 estimates
Expected range-$21.10–$4.21Low to high EPS
Dec 2026$11.28Street EPS consensus
Dec 2027$16.43Street EPS consensus
Dec 2028$18.22Street EPS consensus

Reported results

Annual financial snapshot

Fiscal period ended Dec 31, 2025.

MetricCurrentPrior
Revenue+2.2% YoY$9.89B$9.68B
Operating income$1.86B$2.16B
Net income$1.29B$1.63B
Operating cash flow$2.2B$2.88B
Capital expenditures($0.15B)($0.15B)

Current context

Related news

Company-linked articles surfaced by Nasdaq.

Zacks

Can These 5 Biotech Stocks Beat Wall Street's Q2 Estimates?

Zacks

The Zacks Analyst Blog Highlights Harmony Biosciences, Acadia Pharmaceuticals, Biogen, Insmed and Agios Pharmaceuticals

Zacks

Biogen Q2 Earnings: Can New Drugs Counter Falling MS Sales?

Evidence

Sources & method

Nasdaq quote →Nasdaq summary →Earnings forecast →Annual financials →Official S&P 500-tracking holdings →

Facts, estimates, and scenarios are kept separate. Analyst targets and EPS expectations are third-party estimates, not MRTNZ forecasts. Index weight uses the official IVV portfolio as the denominator. Illustrative research, not investment advice.